CRWD:NASDAQCrowdStrike Holdings, Inc. Analysis
Data as of 2026-03-09 - not real-time
$434.13
Latest Price
8/10Risk
Risk Level: High
Executive Summary
CrowdStrike posted a robust fourth‑quarter revenue of $1.31 billion, beating estimates, and reported a 47% year‑over‑year jump in net‑new annual recurring revenue, fueling a post‑earnings rally of roughly 10% and an HSBC upgrade to Buy. The company’s revenue growth remains strong at 23% YoY with an impressive 74.8% gross margin, though operating profitability is still thin (1% operating margin) and net profit remains negative. Valuation metrics are stretched: the forward P/E sits near 70× and the price‑to‑book is above 24×, while a discounted cash‑flow model suggests a fair value of about $245, implying the stock trades at a ~13% premium to intrinsic estimates.
Technical indicators show the price (≈$434) sitting below the 20‑, 50‑ and 200‑day SMAs, a bearish trend direction, but a bullish MACD histogram and RSI near 57 suggest limited downside momentum. Volatility is high (≈66% 30‑day) and beta exceeds 1.4, indicating sensitivity to market swings, yet volume is increasing and support around $343 provides a cushion. The combination of strong top‑line growth, elevated valuation, and heightened risk points to a cautious but opportunistic stance.
Technical indicators show the price (≈$434) sitting below the 20‑, 50‑ and 200‑day SMAs, a bearish trend direction, but a bullish MACD histogram and RSI near 57 suggest limited downside momentum. Volatility is high (≈66% 30‑day) and beta exceeds 1.4, indicating sensitivity to market swings, yet volume is increasing and support around $343 provides a cushion. The combination of strong top‑line growth, elevated valuation, and heightened risk points to a cautious but opportunistic stance.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Post‑earnings price rally and upgraded outlook
- Support level near $343 limiting downside
- Increasing trading volume indicating market interest
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained revenue growth and expanding ARR base
- Strong cash generation (free cash flow > $1.6 billion)
- Strategic AI‑driven security offerings enhancing competitive moat
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Valuation remains significantly above DCF fair value
- Profitability has not yet turned positive despite margin expansion
- High volatility and beta suggest continued price swings
Key Metrics & Analysis
Financial Health
Revenue Growth23.30%
Profit Margin-3.38%
P/E Ratio70.3
ROE-4.14%
ROA-1.57%
Debt/Equity18.34
P/B Ratio24.8
Op. Cash Flow$1.6B
Free Cash Flow$1.6B
Industry P/E36.8
Technical Analysis
TrendBearish
RSI57.4
Support$342.72
Resistance$438.28
MA 20$400.47
MA 50$432.36
MA 200$468.95
MACDBullish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$244.52
Target Price$493.85
Upside/Downside13.76%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.48
Volatility65.79%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.